Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma Co's Accounts Payable for the quarter that ended in Mar. 2026 was 円56,698 Mil.
Sumitomo Pharma Co's quarterly Accounts Payable
declined
from Sep. 2025 (円42,046 Mil) to Dec. 2025 (円35,108 Mil) but then
increased
from Dec. 2025 (円35,108 Mil) to Mar. 2026 (円56,698 Mil).
Sumitomo Pharma Co's annual Accounts Payable
declined
from Mar. 2024 (円67,720 Mil) to Mar. 2025 (円38,544 Mil) but then
increased
from Mar. 2025 (円38,544 Mil) to Mar. 2026 (円56,698 Mil).
Sumitomo Pharma Co Accounts Payable Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Sumitomo Pharma Co (TSE:4506) has a Accounts Payable of 円56,698 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Accounts Payable too high?
Sumitomo Pharma Co's current Accounts Payable is 円56,698 Mil. Overall, Sumitomo Pharma Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Accounts Payable compare to ZTS?
Sumitomo Pharma Co's Accounts Payable of 円56,698 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Accounts Payable is 円56,698 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円844.26, compared to a current price of 円1,290.50 — trading 52.9% above its estimated fair value. The current Accounts Payable is 円56,698 Mil. Sumitomo Pharma Co's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Accounts Payable is 円56,698 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of 円1,290.50 is trading 52.9% above its estimated GF Value™ of 円844.26.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for TSE:4506:
Accounts Payable: 円56,698 Mil
GF Value™: 円844.26 vs. price of 円1,290.50 (52.9% above fair value)
No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
64GF Score
Get the complete analysis for TSE:4506
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4506 has been successfully added to your 
